Alto Neuroscience, Inc. (ANRO) surged 53.51 percent to $6.77 on Friday after the company announced that the U.S. Food and Drug Administration granted Fast Track designation to its investigational drug ALTO-101 for the treatment of cognitive impairment associated with schizophrenia. Shares opened at $4.76 and traded between $4.72 and $7.15 during the session, compared with a prior close of $4.41 on the New York Stock Exchange. Current bids are at $6.63 with asks at $6.64. Trading volume spiked to 42.47 million shares, far above the average of 100,207. The stock has traded between $1.60 and $15.04 over the past 52 weeks.
The PDE4 inhibitor has shown pro-cognitive effects in healthy volunteers, and a Phase 2 proof-of-concept trial in CIAS patients is ongoing.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.